华特达因(000915) - 2015 Q3 - 季度财报

Financial Performance - Revenue for the reporting period was ¥268,346,346.02, representing a decrease of 19.36% year-over-year [7]. - Net profit attributable to shareholders was ¥19,332,031.38, down 69.31% compared to the same period last year [7]. - Basic earnings per share decreased by 68.57% to ¥0.11, while diluted earnings per share also fell by 68.57% to ¥0.11 [7]. - The weighted average return on net assets was 1.89%, a decrease of 5.50 percentage points year-over-year [7]. - The net profit after deducting non-recurring gains and losses was ¥18,660,908.25, a decrease of 62.85% year-over-year [7]. - Net profit attributable to the parent company decreased by 39.98% to ¥83.08 million, primarily due to reduced net profit from pharmaceutical products [22]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥174,448,626.45, down 20.64% compared to the previous year [7]. - Cash received from investment increased by 677.78% to ¥140 million, attributed to the maturity of bank wealth management products [22]. - Investment income increased by 274.10% to ¥1.85 million, mainly from returns on bank wealth management products [22]. - The company invested ¥1 billion in a technology exchange center and ¥100 million in a private equity fund for capital health industry investments [25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,147 [11]. - The largest shareholder, Shandong Shanda Industry Group Co., Ltd., held 21.55% of the shares, totaling 38,841,800 shares [13]. Receivables and Assets - Accounts receivable decreased by 34.70% to ¥207.75 million due to the maturity of bank acceptance bills [20]. - Other receivables decreased by 45.88% to ¥32.50 million primarily due to a reduction in receivable amounts [20]. - Long-term receivables increased by 33.34% to ¥48.75 million due to an increase in installment sales [20]. - Construction in progress increased by 51.03% to ¥117.06 million due to the addition of new projects [20]. - Development expenses increased by 75.67% to ¥20.01 million, primarily due to increased pharmaceutical development costs [20]. Non-Operating Income and Liabilities - The company reported non-operating income of ¥1,618,241.38 for the period [9]. - The company repaid bank loans totaling ¥91.58 million, an increase of 60.97% compared to the previous period [24].